Kindeva Drug Delivery, a global CDMO, has successfully completed its first registration batch on its groninger high-volume vial line at its state-of-the-art Bridgeton, MO facility, marking the facility’s readiness to provide injectable fill-finish capabilities.
 
Denis Johnson, Chief Operating Officer at Kindeva, said, “The completion of the first registration batch at the Bridgeton facility represents a significant milestone. This is the first of four lines planned to be installed in the next 18 months. Additionally, we are pleased to announce we have just successfully completed the Factory Acceptance Testing (FAT) on the first of two Optima syringe/cartridge filling lines planned for the new facility.”
 
The first Optima line is expected to arrive in November 2024, with qualification slated for completion in 1Q25. By the end of 2025, Kindeva anticipates both Optima lines will be fully qualified, enabling production capacity exceeding 100 million units annually across vials, cartridges, and syringes.